Fed Circuit rules against Mylan in patent dispute over epilepsy drug
Generic-drug manufacturers Mylan Pharmaceuticals, Breckenridge Pharmaceutical and Alembin Pharmaceuticals have lost their bid to prove that claims in a patent owned by US company Research Corporation Technologies, were invalid on the grounds of obviousness.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
27 March 2017 The Patent Trial and Appeal Board has upheld a Research Corporation Technologies patent for anti-epileptic drug Vimpat in a case brought by Argentum Pharmaceuticals.
27 March 2017 The Patent Trial and Appeal Board has upheld a Research Corporation Technologies patent for anti-epileptic drug Vimpat in a case brought by Argentum Pharmaceuticals.
27 March 2017 The Patent Trial and Appeal Board has upheld a Research Corporation Technologies patent for anti-epileptic drug Vimpat in a case brought by Argentum Pharmaceuticals.